Clinical Edge Journal Scan

Internet-based interventions do not reduce fear of breast cancer recurrence


 

Key clinical point: The Internet–based-targeted psychological interventions fail to reduce fear of recurrence among early breast cancer survivors.

Major finding: The Fear of Cancer Recurrence Inventory (FCRI) scores significantly decreased at 8 weeks from baseline in all groups ( P less than .001). The magnitude of reduction in FCRI scores was similar in cognitive-behavioral interventions and attention controls.

Study details: The randomized controlled FoRtitude study of breast cancer survivors who completed primary treatment. The survivors were randomly assigned to 4 Internet-based interventions or controls. The 4 interventions given for 4 weeks consisted of 3 cognitive behavioral interventions (relaxation, cognitive restructuring, and worry practice vs. attention controls) and telecoaching (motivational interviewing to improve adherence vs. no telecoaching).

Disclosures: This work was supported by the National Cancer Institute at the National Institutes of Health and the ECOG-ACRIN Medical Research Foundation. The authors did not disclose any conflict of interest.

Source: Wagner LI. J Natl Cancer Inst. 2021 May 31. doi: 10.1093/jnci/djab100 .

Recommended Reading

Promising HER2+/HR– breast cancer survival with de-escalated therapy
MDedge Hematology and Oncology
Freezing breast cancer to death avoids surgery: Why not further along?
MDedge Hematology and Oncology
DCIS: Biosignature helps guide postlumpectomy decisions
MDedge Hematology and Oncology
Clinical Edge Journal Scan Commentary: Breast Cancer July 2021
MDedge Hematology and Oncology
Adjuvant olaparib yields survival benefit in HER2-negative BRCA1/2 breast cancer
MDedge Hematology and Oncology
Residual TNBC: Platinum therapy does not improve outcomes
MDedge Hematology and Oncology
Adding ribociclib extends survival in HR-positive, HER-negative breast cancer
MDedge Hematology and Oncology
HR-positive breast cancer: Aromatase inhibitors-based treatment yields survival benefit
MDedge Hematology and Oncology
TNBC: Lower recurrence risk with breast-conserving surgery compared with mastectomy
MDedge Hematology and Oncology
Metastatic breast cancer: Survival has improved over time
MDedge Hematology and Oncology